Peter Buhl Jensen
Chairman of the Board. Peter Buhl Jensen is Professor of Clinical Oncology, MD, DMSc., Founder of TopoTarget 2000 and CEO 2001-2010.
As a CEO of TopoTarget, Peter Buhl Jensen build a cutting edge pipeline via M&A of 3 companies, listed TopoTarget on the Copenhagen Stock Exchange 2005 and raised more than 1 billion DKK. Savene® was approved and launched in 2006 in EU, in 2007 Totect® was approved in the USA and in February 2010 Topotarget signed a belinostat partnering deal for USA with a potential value of 350 million USD plus double digit royalty. Serves on the board of directors of Vecata A/S, Proof of Concept Board- DTU-KU-Risø, Symbion A/S, and Wnt Research AB.
